| Schedule of Disaggregation of Revenue |
The following table summarizes revenue by source as follows: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended September 30, | | Nine Months Ended September 30, | | Major Products/Service Lines (in thousands) | | 2024 | | 2023 | | 2024 | | 2023 | Product revenue, net(1) | | $ | 374,601 | | | $ | 319,508 | | | $ | 1,136,670 | | | $ | 925,848 | | | License and royalty revenues | | 4,133 | | | 438 | | | 6,130 | | | 16,582 | | | Total revenues | | $ | 378,734 | | | $ | 319,946 | | | $ | 1,142,800 | | | $ | 942,430 | |
________________________________ (1)The Company’s product revenue includes PYLARIFY and DEFINITY among other products. This category represents the delivery of physical goods. The Company applies the same revenue recognition policies and judgments for all its principal products. Revenue by product category on a net basis is as follows: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended September 30, | | Nine Months Ended September 30, | | (in thousands) | | 2024 | | 2023 | | 2024 | | 2023 | | PYLARIFY | | $ | 259,756 | | | $ | 215,428 | | | $ | 791,881 | | | $ | 621,419 | | | Other radiopharmaceutical oncology | | — | | | 848 | | | 384 | | | 2,383 | | | Total radiopharmaceutical oncology | | 259,756 | | | 216,276 | | | 792,265 | | | 623,802 | | | DEFINITY | | 76,965 | | | 67,336 | | | 231,629 | | | 206,688 | | | TechneLite | | 20,480 | | | 23,272 | | | 70,380 | | | 65,853 | | | Other precision diagnostics | | 6,282 | | | 5,740 | | | 18,039 | | | 17,002 | | | Total precision diagnostics | | 103,727 | | | 96,348 | | | 320,048 | | | 289,543 | | | Strategic partnerships and other revenue | | 15,251 | | | 7,322 | | | 30,487 | | | 29,085 | | | Total revenues | | $ | 378,734 | | | $ | 319,946 | | | $ | 1,142,800 | | | $ | 942,430 | |
|